BioMed Research International

BioMed Research International / 2017 / Article

Research Article | Open Access

Volume 2017 |Article ID 9747256 |

Qiongxian Yan, Haiou Tong, Shaoxun Tang, Zhiliang Tan, Xuefeng Han, Chuanshe Zhou, "L-Theanine Administration Modulates the Absorption of Dietary Nutrients and Expression of Transporters and Receptors in the Intestinal Mucosa of Rats", BioMed Research International, vol. 2017, Article ID 9747256, 7 pages, 2017.

L-Theanine Administration Modulates the Absorption of Dietary Nutrients and Expression of Transporters and Receptors in the Intestinal Mucosa of Rats

Academic Editor: Anton M. Jetten
Received20 Mar 2017
Revised03 Jun 2017
Accepted15 Jun 2017
Published24 Jul 2017


L-theanine has various advantageous functions for human health; whether or not it could mediate the nutrients absorption is unknown yet. The effects of L-theanine on intestinal nutrients absorption were investigated using rats ingesting L-theanine solution (0, 50, 200, and 400 mg/kg body weight) per day for two weeks. The decline of insulin secretion and glucose concentration in the serum was observed by L-theanine. Urea and high-density lipoprotein were also reduced by 50 mg/kg L-theanine. Jejunal and ileac basic amino acids transporters SLC7a1 and SLC7a9, neutral SLC1a5 and SLC16a10, and acidic SLC1a1 expression were upregulated. The expression of intestinal SGLT3 and GLUT5 responsible for carbohydrates uptake and GPR120 and FABP2 associated with fatty acids transport were inhibited. These results indicated that L-theanine could inhibit the glucose uptake by downregulating the related gene expression in the small intestine of rats. Intestinal gene expression of transporters responding to amino acids absorption was stimulated by L-theanine administration.

1. Introduction

L-theanine, as a non-protein-forming amino acid (AA), contributes to the umami taste and unique flavor of green tea. Its content in tea leaves is closely related to the quality and price of green tea [1, 2]. L-theanine is beneficial for remedying various nutritional and metabolic diseases in human, including providing antiobesity effects [3, 4], suppressing the body weight increases and fat accumulation [3, 5], and exerting antidiabetic effects [6, 7]. L-theanine is transported through the intestinal brush border membrane mainly via neutral AA systems B, A, ASC, N, and L, based on findings that L-theanine inhibited the absorption of glutamine and large neutral amino acids (AAs, leucine, and tryptophan) into organs [810]. Our knowledge data and previous findings also confirmed that most neutral AAs (threonine, valine, methionine, isoleucine, serine, alanine, tyrosine, and leucine) and certain basic AA (lysine) in the serum of L-theanine-administered rats were decreased [8, 11]. These researches indicated that L-theanine could competitively suppress the absorption of AAs.

However, AAs absorption is dependent on the activities of AA transporters located in the brush border membrane of small intestine. Neutral AA transporters, solute carrier family 1, member 5 (SLC1a5) and family 16, member 10 (SLC16a10), are responsible for threonine, serine, alanine, cysteine, glutamine and phenylalanine, tyrosine, and tryptophan transporting, respectively. Basic AA transporters, solute carrier family 7, member 1 (SLC7a1) and member 9 (SLC7a9), are in charge of transporting arginine, lysine, histidine, alanine, serine, cysteine, threonine, asparagine, and glutamine. Acidic AA transporters solute carrier family 1, member 1 (SLC1a1) and member 2 (SLC1a2) transport glutamate and aspartate. It is reported that L-theanine competitively inhibited the uptake of glutamate substrate through solute carrier family 1, member 3 (SLC1a3) and SLC1a2 expressed in cancer cells [12, 13]. However, the expression pattern of glutamate transporter subtypes in tumor cells is different from normal cells. Therefore, it is necessary to investigate the efficacy of L-theanine on glutamate transporters in normal tissues. Whether or not the expression of different AA transport systems is mediated by L-theanine is unknown yet.

Furthermore, it is reported that the fatty accumulation in mice was suppressed by the administration of green tea powder [4] and theanine was responsible for this suppressive effect [3]. Although serum glucose in rats was not changed, the insulin was reduced by oral theanine [14]. These literatures indicate that metabolism of lipid and insulin is regulated by L-theanine. In the enterocytes of rats, there are many transporters and receptors responses to sugar and fatty acids transport, including sodium dependent glucose transporters (SGLTs), glucose transporters, G-protein-coupled receptors, and fatty acid binding protein 2 (FABP2) [1521]. Whether these transporters and receptors involved in the regulation of L-theanine administration on absorption of glucose and lipid is unclear. Based on these questions, we measured the nutrient content in the blood and mRNA expression of related transporters and receptors in small intestine of rats after the intragastric administration of L-theanine for two weeks, aiming at figuring out the preliminary L-theanine-induced regulation mechanism in nutrients absorption in rats.

2. Material and Methods

2.1. Experimental Design

This experiment was conducted according to the animal care guidelines of the Animal Care Committee, Institute of Subtropical Agriculture, the Chinese Academy of Sciences, Changsha city, Hunan province, China (number KYNEAAM-2013-0009). Sixty-four Sprague Dawley (SD) rats which are 3 weeks old weighing 74–92.2 g were used as experimental animals. The management of SD rats and L-theanine administration experiment was the same as Li et al. [22]. The animals were individually housed in plastic cages under laboratory conditions (25 ± 3°C, 70 ± 5% relative humidity, good ventilation, and a 12-h light-dark cycle) and had free access to food and pure water. After three days of adaptation, SD rats were randomly divided into four treatment groups. Each group contained eight male rats and eight female rats. During fasting (15:00–17:00 h), rats in the treatments received gastric intubation of four different doses of L-theanine (0, 50, 200, and 400 mg/kg body weight/day), respectively. L-theanine was freshly dissolved in 0.9% NaCl solution in advance before intubation every day. 1 mL of the L-theanine solution was daily administered to each rat for two weeks.

2.2. Blood and Tissue Samples Collection

At the end of the experiment, SD rats were fasted overnight and anesthetized by ether for 4 min, and then blood was collected from the jugular vein into tubes without anticoagulant. The blood samples were centrifuged at 3500 rpm for 15 min at 4°C, and then serum samples were collected and stored at −80°C until assay. The whole jejunum and ileum segments were collected and rinsed with ice-cold saline (0.9% NaCl wt/vol). Then the mucosae were carefully removed, quickly frozen in liquid nitrogen, and stored at −80°C prior to subsequent analyses.

2.3. Analysis of Serum

The glucose, total cholesterol, triglyceride (TG), urea, low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) were determined by automatic biochemistry analyzer (Synchron Clinical System CX4 PRO, Beckman Coulter, USA) according to the instructions. Insulin was assayed by the ELISA kit purchased from Huamei Biotechnology Co., Ltd. (Wuhan, Hubei, China). Non-esterified fatty acids (NEFA) were measured by kit produced by Nanjing Jiancheng Bioengineering Institute (Nanjing, Jiangsu, China).

2.4. Real-Time Quantitative PCR

Total RNA was isolated from the mucosa of jejunum and ileum using the Trizol Reagent (Invitrogen, USA), and cDNA was synthesized using the Revert Aid First Strand cDNA synthesis kit (Applied Biosystems, Thermo Fisher Scientific, USA). For relative quantification of gene expression, the ABI Prism 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster, CA) was used. Primers were designed using the Primer 3 plus program, and sequences are listed in Table 1. The reaction system contained 5 μL SYBR® Premix Ex Taq™ (2), 0.4 μL PCR forward primer (10 μM), 0.4 μL PCR reverse primer (10 μM), 0.2 μL ROX reference dye (50), 1.0 μL cDNA, and 3 μL sterilized ddH2O. The thermal profile for all reactions was 30 s at 95°C, then 40 cycles of denaturation at 95°C for 5 s, and annealing at 60°C for 30 s. Each reaction was completed with a melting curve analysis to ensure the specificity of the reaction. All the samples were analyzed in duplicate, and the relative amount of each specific transcript was obtained after normalization against the endogenous control β-actin. The relative amounts of target genes were quantified according to the method [23].

GeneGenBank accessionPrimerLength (bp)

β-actin NM_031144.3Forward-TGTCACCAACTGGGACGATA

2.5. Statistical Analysis

Statistical analyses were conducted by one-way analysis of variance (ANOVA) using the Mixed Proc of SAS (version 8.2, SAS Institute, Cary, NC, USA). The main effect tested was the dose of L-theanine. When indicated by ANOVA, means were separated using least significant differences. Significance was declared at P < 0.05.

3. Results

As shown in Table 2, glucose concentration was decreased by 400 mg/kg L-theanine administration compared to the control group (0 mg/kg L-theanine administration) (P < 0.05). Insulin concentration was linearly decreased by L-theanine administration (P < 0.001). There were no differences (P > 0.05) in the serum cholesterol, TG, NEFA, and LDL concentrations among the L-theanine treatments. Concentrations of urea and HDL were decreased by 50 mg/kg L-theanine treatment compared to the control group (P < 0.05).

ItemTreatments (mg/kg BWd) value

Average daily gain, g/d5.24 ± 0.176.01 ± 0.176.15 ± 0.175.98 ± 0.170.038<0.01
Glucose, mM5.65 ± 0.295.31 ± 0.295.74 ± 0.294.77 ± 0.30NSNS
Insulin, uIU/mL43.2 ± 2.1841.7 ± 2.1826.3 ± 2.2619.0 ± 3.08<0.001NS
Cholesterol, mM2.23 ± 0.092.08 ± 0.092.13 ± 0.092.05 ± 0.09NSNS
Triglyceride, mM1.23 ± 0.071.21 ± 0.071.02 ± 0.071.16 ± 0.07NSNS
NEFA, mM1.27 ± 0.131.35 ± 0.101.45 ± 0.111.31 ± 0.10NSNS
Urea, mM5.42 ± 0.164.85 ± 0.165.70 ± 0.165.38 ± 0.17NSNS
LDL, mM0.339 ± 0.020.341 ± 0.020.354 ± 0.020.347 ± 0.02NSNS
HDL, mM1.74 ± 0.061.52 ± 0.061.60 ± 0.061.60 ± 0.06NSNS

BW: body weight, NEFA: non-esterified fatty acids, LDL: low-density lipoprotein, HDL: high-density lipoprotein, and NS: not significant. Means within a row not bearing a common superscript letter differ (). Data were reported as mean ± SE. Data of average daily gain were cited by Tong et al. (2016).

Transcript levels of intestinal AA transporters in the intestine of rats are shown in Table 3. Expression of acidic AA transporter SLC1a1 was upregulated in the jejunum and ileum (Quadratic, P < 0.001), while jejunal SLC1a2 transcript was linearly decreased (P < 0.001) with the increasing doses of L-theanine but increased by L-theanine treatments in the ileum (Quadratic, P < 0.05). Expression of neutral AA transporter SLC1a5 was increased by doses of L-theanine (jejunum, Linear, P < 0.001; ileum, Linear and Quadratic, P < 0.001); therein the maximal values both occurred in the 400 mg/kg L-theanine treatment. Another neutral AA transporter SLC16a10 expression in the jejunum and ileum was upregulated by doses of L-theanine (Quadratic, P < 0.001). Basic AA transporters SLC7a1 (jejunum, Linear, P < 0.01; ileum, Linear and Quadratic, P < 0.001) and SLC7a9 expression (jejunum, Quadratic, P < 0.001; ileum, Linear and Quadratic, P < 0.001) was increased with the increasing doses of L-theanine.

ItemTreatments (mg/kg BWd) value

 SLC1a11.001.71 ± 0.437.70 ± 0.501.12 ± 0.55NS<0.001
 SLC1a21.000.34 ± 0.060.63 ± 0.070.23 ± 0.07<0.001NS
 SLC1a51.001.77 ± 0.431.61 ± 0.383.49 ± 0.41<0.001NS
 SLC16a101.007.17 ± 0.845.25 ± 0.793.83 ± 0.68NS<0.001
 SLC7a11.008.40 ± 0.703.93 ± 0.908.88 ± 1.280.0017NS
 SLC7a91.006.40 ± 0.6010.9 ± 0.661.70 ± 0.60NS<0.001
 SLC1a11.004.89 ± 0.355.11 ± 0.391.25 ± 0.39NS<0.001
 SLC1a21.001.47 ± 0.291.86 ± 0.241.02 ± 0.44NS0.01
 SLC1a51.001.45 ± 0.350.94 ± 0.374.45 ± 0.45<0.001<0.001
 SLC16a101.008.27 ± 0.2713.1 ± 0.631.52 ± 0.77NS<0.001
 SLC7a11.001.71 ± 0.341.18 ± 0.364.62 ± 0.45<0.001<0.001
 SLC7a91.001.93 ± 0.427.21 ± 0.522.09 ± 0.42<0.001<0.001

BW: body weight, SLC1a1: solute carrier family 1, member 1, SLC1a2: solute carrier family 1, member 2, SLC1a5: solute carrier family 1, member 5, SLC16a10: solute carrier family 16, member 10, SLC7a1: solute carrier family 7, member 1, SLC7a9: solute carrier family 7, member 9, and NS: not significant. Means within a row not bearing a common superscript letter differ (). Data were reported as mean ± SE.

Gene expressions of glucose transporters and receptors in the intestine of rats are shown in Table 4. Transcript level of SGLT1 in the jejunum was stimulated (P < 0.05) by 400 mg/kg L-theanine compared to the 200 mg/kg L-theanine treatment, while in the ileum it was downregulated (Quadratic, P < 0.001); therein a minimum value appeared at the 200 mg/kg L-theanine group. SGLT3 expression in the jejunum and ileum was decreased by L-theanine treatment (jejunum, Linear, P < 0.001; ileum, Linear and Quadratic, P < 0.001). Comparing with the 50 mg/kg L-theanine treatment, jejunal GLUT2 expression was suppressed (P < 0.05) by 200 mg/kg L-theanine. Ileac GLUT2 expression was upregulated (P < 0.01) by 50 mg/kg L-theanine and then inhibited (P < 0.05) by high doses of L-theanine treatments compared to 50 mg/kg L-theanine. Jejunal GLUT5 expression was inhibited (P < 0.05) by high doses of L-theanine treatment compared to the control group, while its expression in the ileum was linearly decreased (P < 0.01) by increasing doses of L-theanine.

ItemTreatments (mg/kg BWd) value

 SGLT11.001.14 ± 0.200.80 ± 0.211.65 ± 0.21NSNS
 SGLT31.001.06 ± 0.150.53 ± 0.160.03 ± 0.15<0.001NS
 GLUT21.001.44 ± 0.20.77 ± 0.201.12 ± 0.17NSNS
 GLUT51.000.16 ± 0.080.72 ± 0.100.68 ± 0.10NSNS
 SGLT11.000.60 ± 0.120.17 ± 0.111.10 ± 0.09NS<0.001
 SGLT3 1.000.61 ± 0.070.26 ± 0.060.01 ± 0.005<0.001<0.001
 GLUT21.003.07 ± 0.301.31 ± 0.331.99 ± 0.30NSNS
 GLUT51.000.58 ± 0.100.53 ± 0.110.46 ± 0.110.003NS

BW: body weight, SGLT1: sodium dependent glucose transporter 1, SGLT3: sodium dependent glucose transporter 3, GLUT2: glucose transporter protein, member 2, GLUT5: glucose transporter protein, member 5, and NS: not significant. Means within a row not bearing a common superscript letter differ (P < 0.05). Data were reported as mean ± SE.

The mRNA abundance of the fatty acid transporters and receptors in the intestine of rats is shown in Table 5. Jejunal FATP expression was decreased by L-theanine treatments (Quadratic, P < 0.01), while its expression levels in the treatments of 50 and 400 mg/kg L-theanine were lower (P < 0.01) than that of control group and 200 mg/kg L-theanine treatment. Ileac FATP expression was not affected by L-theanine treatments (P > 0.05). Jejunal GPR43 expression was unchanged by L-theanine treatments (P > 0.05). However, its expression in the ileum of 50 mg/kg L-theanine treatment was decreased (P < 0.05) compared with control group and 200 mg/kg L-theanine treatment. GPR120 (jejunum, Linear and Quadratic, P < 0.001; ileum, Linear, P < 0.001) and FABP2 (jejunum, Linear, P < 0.001; ileum, Linear and Quadratic, P < 0.001) expression levels were both suppressed by L-theanine treatments.

ItemTreatments (mg/kg BW·d)P value

 FATP1.000.27 ± 0.031.86 ± 0.070.40 ± 0.03NS0.007
 GPR431.000.79 ± 0.491.23 ± 0.570.86 ± 0.61NSNS
 GPR1201.000.25 ± 0.030.18 ± 0.030.06 ± 0.03<0.001<0.001
 FABP21.000.52 ± 0.080.51 ± 0.080.09 ± 0.08<0.001NS
 FATP1.001.52 ± 0.191.00 ± 0.191.76 ± 0.39NSNS
 GPR431.000.56 ± 0.130.72 ± 0.141.02 ± 0.14NS0.07
 GPR1201.000.36 ± 0.110.64 ± 0.110.21 ± 0.12<0.001NS
 FABP21.000.38 ± 0.050.16 ± 0.050.08 ± 0.05<0.001<0.001

BW: body weight, FATP: fatty acid transport protein, GPR43: G-protein-coupled receptor 43, GPR120: G-protein-coupled receptor 120, FABP2: fatty acid binding protein 2, and NS: not significant. Means within a row not bearing a common superscript letter differ (P < 0.05). Data were reported as mean ± SE.

4. Discussion

To the best of our knowledge, this experiment is a new attempt to investigate the link between serum nutrients and the expression of nutrient-associated transporters and receptors in the small intestine of L-theanine-administered rats. In this study, the declines of glucose, insulin, and urea in the serum were observed by L-theanine administration, indicating that L-theanine could inhibit the absorption of glucose, nitrogen, and secretion of insulin. Our results are partly in line with the data of Yamada et al. (2008) which observed reduced insulin level with unchanged glucose concentration in the serum of rats administrated by 4 g/kg oral L-theanine. These results are inconsistent with the findings of Zheng et al. (2004) which discovered that TG and NEFA levels in the serum of mice were decreased by 0.03% L-theanine administration. This discrepancy appears to be due to the dosage of L-theanine ingested, method of administration, and experimental period.

The upregulating effects of L-theanine are reflected in the AA transporters expression at the mRNA level in small intestine in this study, except SLC1a2. This finding can partly explain the increased AAs concentrations in rat serum after L-theanine ingestion [11], including acidic acid (aspartic acid and glutamic acid), neutral acid (glutamine), and basic acid (histidine) (see Supplemental Table in [11]; see Supplementary Material available online at, indicating that L-theanine promotes the AAs absorption in rat small intestine. The opposing effect of L-theanine on jejunal SLC1a2 expression was observed, reflecting that asparagine absorption in the jejunum might be blocked by L-theanine. Although direct evidences about the regulatory mechanism of AA transporters transcription by L-theanine are lacking, previous literatures showed that activating transcription factor 4 (ATF4) could transcriptionally upregulate SLC7a1 [24] and regulatory factor X proteins (RFXs) induced mRNA of SLC1a1 [25]. After MatInspector online analysis [26], we find that there are ATF4 binding sites in the promoter regions of SLC7a1 (between nucleotides +10 and +18) and SLC7a9 (between nucleotides −155 and −146) genes and RXFs located in SLC1a1 (between nucleotides −239 and −86) promoter sequence. Additionally, elements for E-box binding factors (EBOX) and cAMP-responsive element binding proteins (CREB) binding are identified in the promoter sequences of SLC1a5, SLC7a1, and SLC7a9 genes. Therefore, we speculated that L-theanine, as an amino acid, changed SLC1a1, SLC1a5, SLC7a1, and SLC7a9 mRNA transcription via acting with ATF4, RXF, EBOX, and CREB proteins.

Glucose transporting from the intestinal lumen to the blood mainly depends on Na+-glucose cotransporter SGLT1, which absorbs glucose and galactose and the passive glucose transporter GLUT2, which acts as a glucose sensor [2730]. SGLT3 is also a glucose sensor in cholinergic neurons neighboring enterocytes and induces membrane currents upon Na+-glucose binding [27]. GLUT5 is primarily in charge of fructose absorption into the cytosol. Although decreases in SGLT1 and GLUT2 mRNA abundance in the intestine of rats receiving 200 mg/kg L-theanine, in which glucose absorption was declined, were not observed in this study, we found that intestinal SGLT3 and ileac GLUT5 transcripts in L-theanine-ingested rats were decreased in a dose-dependent manner. These results indicated that rats intestinal GLUT2 was less impressible than GLUT5 to L-theanine administration at the transcriptional level, and SGLT3 and GLUT5 genes rather than SGLT1 and GLUT2 play a role in intestinal glucose absorption of L-theanine-ingested rats. It is reported that period circadian clock 1 (PER1) exerted an indirect suppressive effect on rat SGLT1 promoter [31] and hepatic nuclear factors (HNF) regulated SGLT1 and GLUT2 promoter activities [32, 33]. By analyzing [26], we also identified HNF-element located in SGLT3 and peroxisome proliferator-activated receptor (PPARG) element encompassed in GLUT5 promoter regions. Therefore, we predicted that L-theanine may target transcription factors (PER1, HNF, and PPARG) and further inhibit the expression of glucose transporters mRNA.

It is reported that GPR43 binds short-chain fatty acids, whereas GPR120 responds to medium and long chain fatty acids [34, 35]. FABP2 also displays high-affinity binding for long chain fatty acids and is believed to be involved with uptake and trafficking of lipids in the intestine [21]. In the present study, GPR120 and FABP2 transcripts in jejunum and ileum were decreased by L-theanine. Jejunal FATP mRNA was also suppressed by 50 mg/kg and 400 mg/kg L-theanine. However, triglyceride and cholesterol contents in the serum of L-theanine-treated rats were not affected (Table 2). These results state that the intestinal uptake of dietary fatty acids might have been inhibited by L-theanine. Further research is needed to explore the regulatory mechanism of L-theanine on intestinal uptake of dietary lipids.

In summary, L-theanine administration had decreased serum glucose probably by inhibiting intestinal SGLT3 and GLUT5 mRNA expression in rats. Dietary fatty acids uptake might be suppressed by downregulating GPR120 and FABP2 transcripts in the intestine of rats. Meanwhile, intestinal transporters responding to AAs absorption were upregulated by L-theanine administration. Our data provide theoretical basis for further investigation of L-theanine and nutrients interaction.


AA:Amino acid
ATF4:Activating transcription factor 4
cDNA:Complementary DNA
CREB:cAMP-responsive element binding proteins
ddH2O:Distilled water
EBOX:E-box binding factors
ELISA:Enzyme-linked immunosorbent assay
FABP2:Fatty acid binding protein 2
FATP:Fatty acid transport protein
GLUT2:Glucose transporter protein, member 2
GLUT5:Glucose transporter protein, member 5
GPR43:G-protein-coupled receptor 43
GPR120:G-protein-coupled receptor 120
HDL:High-density lipoprotein cholesterol
HNF:Hepatic nuclear factors
LDL:Low-density lipoprotein cholesterol
mRNA:Messenger RNA
NEFA:Non-esterified fatty acids
PER1:Period circadian clock 1
PPARG:Peroxisome proliferator-activated receptor
RFXs:Regulatory factor X proteins
SLC1a1:Solute carrier family 1, member 1
SLC1a2:Solute carrier family 1, member 2
SLC1a5:Solute carrier family 1, member 5
SLC16a10:Solute carrier family 16, member 10
SLC7a1:Solute carrier family 7, member 1
SLC7a9:Solute carrier family 7, member 9
SGLT1:Sodium dependent glucose transporter 1
SGLT3:Sodium dependent glucose transporter 3
SD:Sprague Dawley

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.


This work was supported by the National Natural Science Foundation of China (Grant nos. 31402112, 31320103917, and 31172234), Strategic Priority Research Program-Climate Change: Carbon Budget and Relevant Issues (Grant no. XDA05020700), Youth Innovation Team Project of ISA, CAS (2017QNCXTD_ZCS), and Hunan Provincial Creation Development Project (2013TF3006).

Supplementary Materials

Effects of L-Theanine administration on serum amino acids profiles in rat.

  1. Supplementary Material


  1. D. C. Chu, “Green tea-its cultivation, processing of the leaves for drinking materials, and kinds of green tea,” in Chemistry and Applications of Green Tea, T. Yamamoto, L. R. Juneja, D. C. Chu, and M. Kim, Eds., pp. 1–11, CRC Press, Boca Raton, 1997. View at: Google Scholar
  2. Q. V. Vuong, M. C. Bowyer, and P. D. Roach, “L-Theanine: Properties, synthesis and isolation from tea,” Journal of the Science of Food and Agriculture, vol. 91, no. 11, pp. 1931–1939, 2011. View at: Publisher Site | Google Scholar
  3. G. Zheng, K. Sayama, T. Okubo, L. R. Juneja, and I. Oguni, “Anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, in mice,” In Vivo, vol. 18, no. 1, pp. 55–62, 2004. View at: Google Scholar
  4. K. Sayama, S. Lin, G. Zheng, and I. Oguni, “Effects of green tea on growth, food utilization and lipid metabolism in mice,” In Vivo, vol. 14, no. 4, pp. 481–484, 2000. View at: Google Scholar
  5. Y. Takagi, S. Kurihara, N. Higashi et al., “Combined administration of L-cystine and L-theanine enhances immune functions and protects against influenza virus infection in aged mice,” Journal of Veterinary Medical Science, vol. 72, no. 2, pp. 157–165, 2010. View at: Publisher Site | Google Scholar
  6. K. Matsumoto, S. Yamamoto, Y. Yoshikawa et al., “Antidiabetic activity of Zn(II) complexes with a derivative of L-glutamine,” Bulletin of the Chemical Society of Japan, vol. 78, no. 6, pp. 1077–1081, 2005. View at: Publisher Site | Google Scholar
  7. N. Kajiwara, Y. Yoshikawa, H. Yasui, and K. Matsumoto, “Experimental observations of anti-diabetic activity of zinc complexes with theanine,” Annals of Nutrition and Metabolism, vol. 63, pp. 1632–1632, 2013. View at: Google Scholar
  8. T. Terashima, J. Takido, and H. Yokogoshi, “Time-dependent changes of amino acids in the serum, liver, brain and urine of rats administered with theanine,” Bioscience, Biotechnology and Biochemistry, vol. 63, no. 4, pp. 615–618, 1999. View at: Publisher Site | Google Scholar
  9. S. Kitaoka, H. Hayashi, H. Yokogoshi, and Y. Suzuki, “Transmural potential changes associated with the in vitro absorption of theanine in the guinea pig intestine,” Bioscience, Biotechnology and Biochemistry, vol. 60, no. 11, pp. 1768–1771, 1996. View at: Publisher Site | Google Scholar
  10. T. Kakuda, E. Hinoi, A. Abe, A. Nozawa, M. Ogura, and Y. Yoneda, “Theanine, an ingredient of green tea, inhibits [3H] glutamine transport in neurons and astroglia in rat brain,” Journal of Neuroscience Research, vol. 86, no. 8, pp. 1846–1856, 2008. View at: Publisher Site | Google Scholar
  11. H. O. Tong, C. J. Li, Q. X. Yan, Z. L. Tan, and X. F. Han, “Effects of L-theanine on serum and liver amino acid compositions in weaning rats,” Food science, pp. 247–252, 2016. View at: Google Scholar
  12. T. Sugiyama, Y. Sadzuka, K. Tanaka, and T. Sonobe, “Inhibition of glutamate transporter by theanine enhances the therapeutic efficacy of doxorubicin,” Toxicology Letters, vol. 121, no. 2, pp. 89–96, 2001. View at: Publisher Site | Google Scholar
  13. T. Sugiyama and Y. Sadzuka, “Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents,” Biochimica et Biophysica Acta - Reviews on Cancer, vol. 1653, no. 2, pp. 47–59, 2003. View at: Publisher Site | Google Scholar
  14. T. Yamada, Y. Nishimura, T. Sakurai et al., “Administration of theanine, a unique amino acid in tea leaves, changed feeding-relating components in serum and feeding behavior in rats,” Bioscience, Biotechnology and Biochemistry, vol. 72, no. 5, pp. 1352–1355, 2008. View at: Publisher Site | Google Scholar
  15. M. Veyhl, J. Spangenberg, B. Püschel et al., “Cloning of a membrane-associated protein which modifies activity and properties of the Na+-D-glucose cotransporter,” Journal of Biological Chemistry, vol. 268, no. 33, pp. 25041–25053, 1993. View at: Google Scholar
  16. G. L. Kellett and P. A. Helliwell, “The diffusive component of intestinal glucose absorption is mediated by the glucose-induced recruitment of GLUT2 to the brush-border membrane,” Biochemical Journal, vol. 350, no. 1, pp. 155–162, 2000. View at: Publisher Site | Google Scholar
  17. S. Tazawa, T. Yamato, H. Fujikura et al., “SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1, 5-anhydro-D-glucitol, and fructose,” Life Sciences, vol. 76, no. 9, pp. 1039–1050, 2005. View at: Google Scholar
  18. S. Karaki, R. Mitsui, H. Hayashi et al., “Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine,” Cell and Tissue Research, vol. 324, no. 3, pp. 353–360, 2006. View at: Publisher Site | Google Scholar
  19. I. Kaji, S.-I. Karaki, R. Tanaka, and A. Kuwahara, “Density distribution of free fatty acid receptor 2 (FFA2)-expressing and GLP-1-producing enteroendocrine L cells in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide,” Journal of Molecular Histology, vol. 42, no. 1, pp. 27–38, 2011. View at: Publisher Site | Google Scholar
  20. S. J. Paulsen, L. K. Larsen, G. Hansen, S. Chelur, P. J. Larsen, and N. Vrang, “Expression of the fatty acid receptor GPR120 in the gut of diet-induced-obese rats and its role in GLP-1 secretion,” PLoS ONE, vol. 9, no. 2, Article ID e88227, 2014. View at: Publisher Site | Google Scholar
  21. A. M. Gajda and J. Storch, “Enterocyte fatty acid-binding proteins (FABPs): different functions of liver and intestinal FABPs in the intestine,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 93, pp. 9–16, 2015. View at: Publisher Site | Google Scholar
  22. C. Li, H. Tong, Q. Yan et al., “L-theanine improves immunity by altering th2/th1 cytokine balance, brain neurotransmitters, and expression of phospholipase c in rat hearts,” Medical Science Monitor, vol. 22, pp. 662–669, 2016. View at: Publisher Site | Google Scholar
  23. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at: Publisher Site | Google Scholar
  24. C. M. Adams, “Role of the transcription factor ATF4 in the anabolic actions of insulin and the anti-anabolic actions of glucocorticoids,” Journal of Biological Chemistry, vol. 282, no. 23, pp. 16744–16753, 2007. View at: Publisher Site | Google Scholar
  25. K. Ma, S. Zheng, and Z. Zuo, “The transcription factor regulatory factor X1 increases the expression of neuronal glutamate transporter type 3,” Journal of Biological Chemistry, vol. 281, no. 30, pp. 21250–21255, 2006. View at: Publisher Site | Google Scholar
  26. K. Cartharius, K. Frech, K. Grote et al., “MatInspector and beyond: promoter analysis based on transcription factor binding sites,” Bioinformatics, vol. 21, no. 13, pp. 2933–2942, 2005. View at: Publisher Site | Google Scholar
  27. A. Díez-Sampedro, B. A. Hirayama, C. Osswald et al., “A glucose sensor hiding in a family of transporters,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 20, pp. 11753–11758, 2003. View at: Publisher Site | Google Scholar
  28. E. M. Wright, D. D. F. Loo, B. A. Hirayama, and E. Turk, “Surprising versatility of Na+-glucose cotransporters: SLC5,” Physiology, vol. 19, no. 6, pp. 370–376, 2004. View at: Publisher Site | Google Scholar
  29. M. A. Hediger, E. Turk, and E. M. Wright, “Homology of the human intestinal Na+/glucose and Escherichia coli Na+/proline cotransporters,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 15, pp. 5748–5752, 1989. View at: Publisher Site | Google Scholar
  30. M. A. Hediger, M. J. Coady, T. S. Ikeda, and E. M. Wright, “Expression cloning and cDNA sequencing of the Na+/glucose co-transporter,” Nature, vol. 330, no. 6146, pp. 379–381, 1987. View at: Publisher Site | Google Scholar
  31. A. Balakrishnan, A. T. Stearns, S. W. Ashley, D. B. Rhoads, and A. Tavakkolizadeh, “PER1 modulates SGLT1 transcription in vitro independent of E-box status,” Digestive Diseases and Sciences, vol. 57, no. 6, pp. 1525–1536, 2012. View at: Publisher Site | Google Scholar
  32. D. B. Rhoads, D. H. Rosenbaum, H. Unsal, K. J. Isselbacher, and L. L. Levitsky, “Circadian periodicity of intestinal Na+/glucose cotransporter 1 mRNA levels is transcriptionally regulated,” Journal of Biological Chemistry, vol. 273, no. 16, pp. 9510–9516, 1998. View at: Publisher Site | Google Scholar
  33. R. Kekuda, P. Saha, and U. Sundaram, “Role of Sp1 and HNF1 transcription factors in SGLT1 regulation during chronic intestinal inflammation,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 294, no. 6, pp. G1354–G1361, 2008. View at: Publisher Site | Google Scholar
  34. N. E. Nilsson, K. Kotarsky, C. Owman, and B. Olde, “Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids,” Biochemical and Biophysical Research Communications, vol. 303, no. 4, pp. 1047–1052, 2003. View at: Publisher Site | Google Scholar
  35. A. J. Brown, S. M. Goldsworthy, A. A. Barnes et al., “The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids,” Journal of Biological Chemistry, vol. 278, no. 13, pp. 11312–11319, 2003. View at: Publisher Site | Google Scholar

Copyright © 2017 Qiongxian Yan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.